215 related articles for article (PubMed ID: 30633746)
41. In brief: heptavalent botulism antitoxin.
Med Lett Drugs Ther; 2014 May; 56(1443):44. PubMed ID: 24869716
[No Abstract] [Full Text] [Related]
42. Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Mar; 59(10):299. PubMed ID: 20300057
[TBL] [Abstract][Full Text] [Related]
43. Workgroup Report by the Joint Task Force Involving American Academy of Allergy, Asthma & Immunology (AAAAI); Food Allergy, Anaphylaxis, Dermatology and Drug Allergy (FADDA) (Adverse Reactions to Foods Committee and Adverse Reactions to Drugs, Biologicals, and Latex Committee); and the Centers for Disease Control and Prevention Botulism Clinical Treatment Guidelines Workgroup-Allergic Reactions to Botulinum Antitoxin: A Systematic Review.
Schussler E; Sobel J; Hsu J; Yu P; Meaney-Delman D; Grammer LC; Nowak-Wegrzyn A
Clin Infect Dis; 2017 Dec; 66(suppl_1):S65-S72. PubMed ID: 29293931
[TBL] [Abstract][Full Text] [Related]
44. Type E botulism.
Horowitz BZ
Clin Toxicol (Phila); 2010 Nov; 48(9):880-95. PubMed ID: 21171846
[TBL] [Abstract][Full Text] [Related]
45. Question 1: In infant botulism, is equine-derived botulinum antitoxin (EqBA) an effective alternative therapy to human-derived botulinum immune globulin (BIG)?
Moneim J
Arch Dis Child; 2018 Sep; 103(9):907-909. PubMed ID: 30007943
[No Abstract] [Full Text] [Related]
46. New targets in the search for preventive and therapeutic agents for botulism.
Anniballi F; Lonati D; Fiore A; Auricchio B; De Medici D; Locatelli CA
Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1075-86. PubMed ID: 25089560
[TBL] [Abstract][Full Text] [Related]
47. A case of type F botulism in southern California.
Richardson WH; Frei SS; Williams SR
J Toxicol Clin Toxicol; 2004; 42(4):383-7. PubMed ID: 15461246
[TBL] [Abstract][Full Text] [Related]
48. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
[TBL] [Abstract][Full Text] [Related]
49. Standardization of the Japanese National Standard, Equine Botulinum Antitoxin Type A, and Factors Affecting Standardization.
Yutani M; Senoh M; Yano H; Kenri T; Iwaki M
Jpn J Infect Dis; 2024 Jan; 77(1):16-20. PubMed ID: 37648491
[TBL] [Abstract][Full Text] [Related]
50. [Foodbourne Botulism: A Forgotten Disease].
Neves P; Vicente J; Cabrera H; Pantazi I
Acta Med Port; 2018 Nov; 31(11):691-693. PubMed ID: 30521463
[TBL] [Abstract][Full Text] [Related]
51. Iatrogenic Botulism: A Case Treated With Botulinum Antitoxin.
Gonul Oner O; Gudek HC; Erturk Cetin O; Demir S
Clin Neuropharmacol; 2023 Mar-Apr 01; 46(2):82-84. PubMed ID: 36728838
[TBL] [Abstract][Full Text] [Related]
52. [Botulism: Diagnosis and Therapy].
Wendt S; Eder I; Wölfel R; Braun P; Lippmann N; Rodloff A
Dtsch Med Wochenschr; 2017 Sep; 142(17):1304-1312. PubMed ID: 28850968
[No Abstract] [Full Text] [Related]
53. Iatrogenic systemic botulism after intragastric botulinum neurotoxin injection: Case report.
Kılboz BB; Ervatan Z; Dumlu R; Akan O
Eur J Neurol; 2023 Oct; 30(10):3394-3396. PubMed ID: 37505930
[TBL] [Abstract][Full Text] [Related]
54. [Poisoning with botulinum neurotoxin--diagnostic difficulties].
Grygorczuk S; Pancewicz S; Kondrusik M; Zajkowska J
Pol Merkur Lekarski; 2000 Aug; 9(50):572-4. PubMed ID: 11081329
[TBL] [Abstract][Full Text] [Related]
55. Early diagnosis and treatment in a child with foodborne botulism.
Proverbio MR; Lamba M; Rossi A; Siani P
Anaerobe; 2016 Jun; 39():189-92. PubMed ID: 26688278
[TBL] [Abstract][Full Text] [Related]
56. Outbreak of type A botulism and development of a botulism surveillance and antitoxin release system in Argentina.
Villar RG; Shapiro RL; Busto S; Riva-Posse C; Verdejo G; Farace MI; Rosetti F; San Juan JA; Julia CM; Becher J; Maslanka SE; Swerdlow DL
JAMA; 1999 Apr; 281(14):1334-8, 1340. PubMed ID: 10208152
[TBL] [Abstract][Full Text] [Related]
57. Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species.
Atassi MZ; Dolimbek BZ; Hayakari M; Middlebrook JL; Whitney B; Oshima M
J Protein Chem; 1996 Oct; 15(7):691-700. PubMed ID: 8968960
[TBL] [Abstract][Full Text] [Related]
58. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism.
Tacket CO; Shandera WX; Mann JM; Hargrett NT; Blake PA
Am J Med; 1984 May; 76(5):794-8. PubMed ID: 6720725
[TBL] [Abstract][Full Text] [Related]
59. Humoral Response of Buffaloes to a Recombinant Vaccine against Botulism Serotypes C and D.
Otaka DY; Barbosa JD; Moreira C; Ferreira MRA; Cunha CEP; Brito ARS; Donassolo RA; Moreira ÂN; Conceição FR; Salvarani FM
Toxins (Basel); 2017 Sep; 9(10):. PubMed ID: 28937601
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism.
Zanetti G; Azarnia Tehran D; Pirazzini M; Binz T; Shone CC; Fillo S; Lista F; Rossetto O; Montecucco C
Biochem Pharmacol; 2015 Dec; 98(3):522-30. PubMed ID: 26449594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
